Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The strategy of combination phase I/II study].

H Murakami1, Y Ohe, N Saijo

  • 1Dept. of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 5, 2000
PubMed
Summary

Combination chemotherapy using novel anticancer drugs requires careful scientific and ethical design. Understanding drug-drug interactions through pharmacokinetic analysis is crucial for optimizing efficacy and safety in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct signal transduction through the tyrosine-containing domains of the granulocyte colony-stimulating factor receptor.

The EMBO journal·1995
Same author

Impaired tumor phenotypes in class II major histocompatibility complex antigen-inducible cells originated from human lung adenocarcinoma.

Biochemical and biophysical research communications·1995
Same author

Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality.

American journal of hematology·1995
Same author

Detection of O2- generation and neutrophil accumulation in rat lungs after acute necrotizing pancreatitis.

Surgery·1995
Same author

Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption.

Journal of cellular biochemistry·1995
Same author

The mode of actions of glyceraldehyde-3-phosphate dehydrogenase identified as an immunoglobulin production stimulating factor.

FEBS letters·1995

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trial Design

Context:

  • Combination chemotherapy is a cornerstone of cancer treatment.
  • Recent advancements include the introduction of novel target-based anticancer drugs.
  • Increased opportunities exist for evaluating combination chemotherapy regimens involving new agents.

Purpose:

  • To outline the scientific and ethical considerations for designing combination chemotherapy phase I/II studies.
  • To highlight the importance of selecting appropriate drugs and administration methods to manage potential drug-drug interactions.
  • To emphasize the necessity of pharmacokinetic analysis for understanding drug interactions and their impact on toxicity and efficacy.

Summary:

  • Combination chemotherapy plays a vital role in cancer treatment, with new drugs becoming increasingly available.

Related Experiment Videos

  • Designing combination phase I/II studies requires careful consideration of drug selection and administration to mitigate drug-drug interactions.
  • Pharmacokinetic analyses are essential for elucidating the mechanisms of drug interactions, thereby influencing treatment toxicity and efficacy.

    • Impact:

    • Improved design and execution of clinical trials for novel combination chemotherapy regimens.
    • Enhanced understanding of drug-drug interactions to optimize anticancer drug efficacy and patient safety.
    • Advancement of high-quality clinical research infrastructure for oncology drug development.